Mon, June 12, 2023

Matthew Biegler Maintained (APTO) at Buy with Increased Target to $50 on, Jun 12th, 2023

Matthew Biegler of Oppenheimer, Maintained "Aptose Biosciences Inc." (APTO) at Buy with Increased Target from $9 to $50 on, Jun 12th, 2023.

Matthew has made no other calls on APTO in the last 4 months.



There are 3 other peers that have a rating on APTO. Out of the 3 peers that are also analyzing APTO, 0 agree with Matthew's Rating of Hold.



These are the ratings of the 3 analyists that currently disagree with Matthew


  • Edward Tenthoff of "Piper Sandler" Maintained at Buy with Decreased Target to $37 on, Wednesday, June 7th, 2023
  • Gregory Renza of "RBC Capital" Maintained at Buy with Decreased Target to $40 on, Wednesday, June 7th, 2023
  • Carey Macrury of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $120 on, Monday, March 27th, 2023